HHS released an advisory opinion regarding certain manufacturer’s refusal to sell 340B drugs through a contract pharmacy. See documents attached. “The Office of the General
https://www.pharmacytimes.com/news/landmark-supreme-court-ruling-state-regulation-of-pbm-reimbursement-rates This will help protect the recent trend by the PBM’s to lower the reimbursement for a 340B drug dispensed vs a non-340B drug. Already
Health Resources and Services Administration (HRSA) released the procedures and requirements for the 340B Program’s Administrative Dispute Resolution (“ADR”). This has been 10 years in
US House letter to HHS regarding Kalderos and their new program called “340B Pay”. 340B Pay will uproot the current 340B cash flow model and
RWC-340B and 340B Grantee Plaintiffs File Lawsuit Against HHS/HRSA to Protect 340B Contract Pharmacy Program from Manufacturer Attacks. See complaint attached.